APRE - CIK 0001781983
Aprea Therapeutics, Inc. trades as APRE. This page tracks Aprea Therapeutics, Inc. through 425 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 424B7 | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| EFFECT | - | 2026-04-29 |
The largest companies sharing Aprea Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Aprea Therapeutics, Inc. reported a net loss of $12.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.